Continuous pump infusion of 5-fluorouracil for 120 h via superficial temporal artery cannulation for advanced T-stage nasopharyngeal carcinoma: a phase I clinical trial

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR1900027372

Enrollment

Unknown

Registered

2019-11-11

Start date

2004-05-01

Completion date

Unknown

Last updated

2019-11-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

advanced T-stage nasopharyngeal carcinoma

Interventions

Case series:5-Fluorouracil

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: Patients with previously untreated NPC; adequate bone marrow, hepatic, heart, and renal action; absence of pregnancy or lactation; absence of previous malignancy or other concomitant malignant disease; and aged 18–70 years with an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.

Exclusion criteria

Exclusion criteria: (1) contraindication of radiotherapy and chemotherapy; (2) unable to clearly describe the therapeutic response; (3) previously been treated with radiotherapy or chemotherapy; (4) suffering from peripheral neurotoxicity above degree II, psychosis, congestive heart failure, angina pectoris, Uncontrolled hypertension, 6 months of myocardial infarction, active infectious diseases and other serious medical complications.

Design outcomes

Primary

Measure	Time frame
maximum tolerated dose;adverse effects;	—

Secondary

Measure	Time frame
survival;	—

Countries

China

Contacts

Public ContactJingBo Wu

Department of Oncology, Affiliated Hospital of Southwest Medical University

wjb6147@163.com+86 13980257136

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026